^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

IGF2 overexpression

i
Other names: IGF2, C11orf43, FLJ44734, IGF-II, Insulin-like growth factor 2
Entrez ID:
Related biomarkers:
7d
Beckwith-Wiedemann syndrome with juvenile fibrous nodules and lobular breast tumors: a case report and review of the literature. (PubMed, Surg Case Rep)
In this case, overexpression of IGF2 suggested a possible relationship between BWS and breast tumors. Moreover, the characteristic clinical features and IGF2 staining predicted the subtype of 11p15.5 molecular defects in this patient.
Review • Journal
|
IGF2 (Insulin-like growth factor 2)
|
IGF2 overexpression
21d
Anillin contributes to prostate cancer progression through the regulation of IGF2BP1 to promote c-Myc and MAPK signaling. (PubMed, Am J Cancer Res)
Meanwhile, we discovered that ANLN can stabilize the proto-oncogene c-Myc and activate the MAPK signaling pathway through IGF2BP1. These findings indicate that ANLN could be a potential therapeutic target in PCa.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • ANLN (Anillin Actin Binding Protein)
|
IGF2 overexpression • IGF2BP1 overexpression
1m
Single-cell and whole-transcriptome sequencing of lymph node metastasis-related gene signature: A large-scale pan-cancer cohort, machine learning and experimental study. (PubMed, Int J Surg)
A novel LNscore-based model was established via comprehensive analysis of LNM-related genes. This model can accurately predict patient survival and drug sensitivity, and reveal the mechanism of LNM in the pan-cancer setting.
Journal • Gene Signature • BRCA Biomarker • IO biomarker • Pan tumor • Machine learning
|
BRCA (Breast cancer early onset) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
|
IGF2 overexpression
1m
Atractylodes macrocephala III suppresses EMT in cervical cancer by regulating IGF2BP3 through ETV5. (PubMed, J Cell Mol Med)
After intersection with our sequencing results, we verified the promotional effect of ETV5 (ETS translocation variant 5) on IGF2BP3 and found that ALT III inhibited ETV5. In general, our research showed that ATL III inhibits the migration and invasion of cervical cancer cells by regulating IGF2BP3 through ETV5.
Journal
|
ETV5 (ETS Variant Transcription Factor 5) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
IGF2 overexpression
1m
Altered Igf2 imprint leads to accelerated adipogenesis and early onset of metabolic syndrome in male mice following gestational arsenic exposure. (PubMed, Chemosphere)
Overexpression of Igf2 was found to be due to arsenic-mediated DNA hypermethylation at the imprinting control region (ICR) located -2kb to -4.4 kb upstream of the H19 gene which caused a reduction in the conserved zinc finger protein (CTCF) occupancy. This further led to persistent activation of the MAPK signaling cascade and enhanced adipogenesis leading to the early onset of MetS in the offspring.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IGF2 (Insulin-like growth factor 2) • H19 (H19 Imprinted Maternally Expressed Transcript) • LEP (Leptin)
|
IGF2 overexpression
3ms
IGF2BP1 facilitates non-small cell lung cancer progression by regulating the KIF2A-mediated Wnt/β-catenin pathway. (PubMed, Funct Integr Genomics)
KIF2A exerted the same functions as IGF2BP1 via the Wnt/β-catenin signaling. In conclusion, IGF2BP1 enhances NSCLC malignant progression by stabilizing KIF2A to modulate the Wnt/β-catenin pathway.
Journal
|
IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
|
IGF2 overexpression • IGF2BP1 overexpression
3ms
BIRC5 facilitates cisplatin-chemoresistance in a m A-dependent manner in ovarian cancer. (PubMed, Cancer Med)
The regulation of its expression and the stability of its mRNA were influenced by m A modifications involving both METTL3 and IGF2BP1. These insights presented BIRC5 as a promising potential therapeutic target for addressing cisplatin resistance in OC.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • METTL3 (Methyltransferase Like 3)
|
BIRC5 expression • IGF2 overexpression • IGF2BP1 overexpression
|
cisplatin
4ms
IGF2 is upregulated by its antisense RNA to potentiate pancreatic cancer progression. (PubMed, Funct Integr Genomics)
IGF2-AS potentiates pancreatic cancer cell proliferation, tumor growth, and metastasis by recruiting HNRNPC via the IGF2-IGF2R regulatory pathway. These discoveries might offer a novel insight for treatment of PC, which may facilitate targeted therapies of PC in clinical practice.
Journal
|
IGF2 (Insulin-like growth factor 2) • HNRNPC (Heterogeneous Nuclear Ribonucleoprotein C)
|
IGF2 overexpression
4ms
IGF2BP2 promotes glycolysis and hepatocellular carcinoma stemness by stabilizing CDC45 mRNA via m6A modification. (PubMed, Cell Cycle)
A test using actinomycin D was performed to gauge the stability of the CDC45 mRNA...In general, IGF2BP2 promoted HCC glycolysis and stemness by stabilizing CDC45 mRNA via m6A modification. [Figure: see text].
Journal
|
CDC45 (Cell Division Cycle 45) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
|
IGF2 overexpression
|
dactinomycin
5ms
Preneoplastic liver colonization by 11p15.5 altered mosaic cells in young children with hepatoblastoma. (PubMed, Nat Commun)
Spatial transcriptomics and single-nucleus RNAseq analyses identify a 60-gene signature in 11p15.5 altered hepatocytes. These data provide insights for 11p15.5 mosaicism detection and its functional consequences during the early steps of carcinogenesis.
Journal
|
IGF2 (Insulin-like growth factor 2) • H19 (H19 Imprinted Maternally Expressed Transcript)
|
IGF2 overexpression • H19 overexpression
5ms
IGF2BP2-meidated mA modification of CSF2 reprograms MSC to promote gastric cancer progression. (PubMed, Cell Death Dis)
Finally, we unveiled that CSF2 induced the ubiquitination of Notch1 to reprogram MSCs. Our study highlights a critical role of IGF2BP2-mediated mA modification of CSF2 in reprogramming MSCs, which presents a promising therapeutic target for gastric cancer.
Journal
|
NOTCH1 (Notch 1) • CSF2 (Colony stimulating factor 2) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
|
IGF2 overexpression
6ms
IGF2BP2 acts as a mA modification regulator in laryngeal squamous cell carcinoma through facilitating CDK6 mRNA stabilization. (PubMed, Cell Death Discov)
Furthermore, we carried out a series of experiments, including hematoxylin & eosin staining, immunohistochemical (IHC) staining, CCK-8, colony formation, transwell, flow cytometry, xenograft tumor model assays, actinomycin D assay, cycloheximide (CHX) assay, methylated mA RNA immunoprecipitation (Me-RIP), RNA immunoprecipitation (RIP) assay, to verify the relevant findings in vivo and in vitro...CDK6 knockdown caused no changes in IGF2BP2 expression, but partially eliminated the promotive effects of IGF2BP2 overexpression on LSCC cells' aggressiveness. Overexpressed IGF2BP2 in LSCC serves as an oncogenic factor, promoting LSCC cell proliferation and invasion in vitro and tumor growth in a xenograft tumor model in vivo through facilitating CDK6 mRNA stabilization.
Journal
|
CDK6 (Cyclin-dependent kinase 6) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
|
IGF2 overexpression • CDK6 expression
|
dactinomycin
6ms
IGF2BP3 Enhances the Growth of Hepatocellular Carcinoma Tumors by Regulating the Properties of Macrophages and CD8 T Cells in the Tumor Microenvironment. (PubMed, J Clin Transl Hepatol)
Furthermore, inhibition of IGF2BP3 combined with anti-CD47 antibody treatment significantly suppressed the growth of hepatoma in Hepa1-6 xenograft tumor mice. IGF2BP3 promoted the infiltration and M2-polarization of macrophages and suppressed CD8 T activation by enhancing CCL5 and TGF-β1 expression, which facilitated the progression of Hepa1-6 xenograft tumor.
Journal
|
CD8 (cluster of differentiation 8) • CCL5 (Chemokine (C-C motif) ligand 5) • TGFB1 (Transforming Growth Factor Beta 1) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
IGF2 overexpression • IGF2 elevation • IGFBP3 elevation
7ms
RNA binding protein IGF2BP1 synergizes with ETV6-RUNX1 to drive oncogenic signaling in B-cell Acute Lymphoblastic Leukemia. (PubMed, J Exp Clin Cancer Res)
Our data suggest a combined impact of the ETV6::RUNX1 fusion protein and RNA binding protein, IGF2BP1 in activating multiple oncogenic pathways in B-ALL which makes IGF2BP1 and these pathways as attractive therapeutic targets and biomarkers.
Journal
|
RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • TNFA (Tumor Necrosis Factor-Alpha) • IGF2 (Insulin-like growth factor 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
|
IGF2 overexpression • IGF2BP1 overexpression • RUNX1 overexpression
7ms
IGF2BP2 promotes ovarian cancer growth and metastasis by upregulating CKAP2L protein expression in an m A-dependent manner. (PubMed, FASEB J)
Overexpression of CKAP2L rescued the tumor-suppressive effect of IGF2BP2 knockdown in OC cells. In conclusion, this study revealed the potential role of IGF2BP2 in tumor progression, at least partially via promoting the translation of CKAP2L in an m A-dependent manner.
Journal
|
IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
|
IGF2 overexpression • IGF2 elevation
7ms
IGF2BP3 drives gallbladder cancer progression by m6A-modified CLDN4 and inducing macrophage immunosuppressive polarization. (PubMed, Transl Oncol)
We manifested IGF2BP3 promotes the aggressive phenotype of gallbladder cancer by stabilizing CLDN4 mRNA in an m6A-dependent manner and induces macrophage immunosuppressive polarization, which might offer a new theoretical basis for against gallbladder cancer.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
IGF2 overexpression • IGF2 elevation • IGFBP3 elevation
10ms
IGF2BP3 aggravates lung adenocarcinoma progression by modulation of PI3K/AKT signaling pathway. (PubMed, Immunopharmacol Immunotoxicol)
Moreover, 740Y-P (PI3K agonist) reversed the inhibitory effects on cell viability and metastasis, and the promotion effect on metastasis caused by IGF2BP3 silencing. Our findings demonstrated that IGF2BP3 contributed to the tumorigenesis of LUAD by activating the PI3K/AKT signaling.
Journal
|
IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
IGF2 overexpression
11ms
Doege-Potter Syndrome in a Patient with Solitary Fibrous Tumor of the Lung (ENDO 2023)
Since he was on high dose steroid for > 3months, hydrocortisone dose was tapered slowly after the surgery...He recovered uneventfully and was discharged home with prednisone 5mg daily and follow up in endocrine clinic... NICTH is a rare paraneoplastic syndrome characterized by low levels of insulin, C-peptide, proinsulin, and beta-hydroxybutyrate. A ratio of IGF-2/IGF-1 more than 10 confirms NICTH; however, normal ratio cannot exclude the diagnosis and factors such as low IGFBP 3 or steroid therapy for other conditions need to be considered. Surgery is the mainstay of treatment.*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation.
Clinical
|
CD34 (CD34 molecule) • IGF1 (Insulin-like growth factor 1) • IGF2 (Insulin-like growth factor 2) • SOX10 (SRY-Box 10) • STAT6 (Signal transducer and activator of transcription 6) • IGFBP3 (Insulin-like growth factor binding protein 3)
|
IGF2 overexpression
|
prednisone
12ms
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma. (PubMed, Mol Cancer Ther)
The antitumor effect of xentuzumab (a monoclonal antibody targeting IGF1/2) alone or in combination with the conventional therapeutic agent cisplatin was assessed in HB cell lines, in PDX-derived HB organoids and in a xenograft HB murine model. These results suggest that IGF2 is an HB actionable driver and that, in preclinical models of HB, the combination of IGF1/2 inhibition with cisplatin induces superior antitumor effects than cisplatin monotherapy. Overall, our study provides a rationale for testing IGF2 inhibitors in combination with cisplatin in HB patients with IGF2 overexpression.
Journal
|
IGF1 (Insulin-like growth factor 1) • IGF2 (Insulin-like growth factor 2) • MIR483 (MicroRNA 483)
|
IGF2 overexpression
|
cisplatin • xentuzumab (BI-836845)
1year
Insulin-like growth factor-2 mRNA-binding protein 3 promotes cell migration, invasion, and epithelial-mesenchymal transition of esophageal squamous cell carcinoma cells by targeting zinc finger E-box-binding homeobox 1 mRNA. (PubMed, Mol Carcinog)
IGF2BP3 was transcriptionally activated in ESCC cell lines via H3K27 acetylation. Our results demonstrate that IGF2BP3 plays a vital role in ESCC cell proliferation, invasion, and metastasis and is a potential therapeutic target for treating ESCC.
Journal
|
IGF2 (Insulin-like growth factor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
IGF2 overexpression
1year
UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma. (PubMed, Int J Oncol)
In summary, the findings indicated the oncogenic roles of UBE2K in PDAC. In addition, IGF2BP3 and UBE2K constitute a functional axis to regulate the malignant progression of PDAC.
Journal
|
IGF2 (Insulin-like growth factor 2) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
|
IGF2 overexpression
1year
Berberine promotes IGF2BP3 ubiquitination by TRIM21 to induce G1/S phase arrest in colorectal cancer cells. (PubMed, Chem Biol Interact)
Overexpression of IGF2BP3 in vitro and in vivo attenuated the inhibition of CRC growth by BBR. This work demonstrated the potential of BBR targeting to IGF2BP3 in improving CRC and provided a new strategy for clinical treatment on CRC as well as novel anticancer drug design based on IGF2BP3 and TRIM21.
Journal
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • IGF2 (Insulin-like growth factor 2) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • TRIM21 (Tripartite Motif Containing 21)
|
IGF2 overexpression
1year
LINC00858 facilitates formation of hepatic metastases from colorectal cancer via regulating the miR-132-3p/IGF2BP1 axis. (PubMed, Biol Chem)
LINC00858 could facilitate CRC tumor growth and hepatic metastases. LINC00858 induced CRC hepatic metastases via regulating miR-132-3p/ IGF2BP1, and this study may deliver a new diagnostic marker for the disease.
Journal
|
IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • MIR132 (MicroRNA 132)
|
IGF2 overexpression • IGF2BP1 overexpression
1year
EMX2OS targeting IGF2BP1 represses Wilms' tumour stemness,epithelial-mesenchymal transition and metastasis. (PubMed, J Genet)
The in vivo tumour growth, stemness and EMT were repressed by EMX2OS through the interaction with IGF2BP1. In conclusion, EMX2OS acted as a tumour suppressor for WT by interacting with IGF2BP1, which might be a novel target for WT diagnosis and therapy.
Journal
|
IGF2 (Insulin-like growth factor 2) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • NANOG (Nanog Homeobox) • MX2 (MX Dynamin Like GTPase 2)
|
IGF2 overexpression • IGF2BP1 overexpression
over1year
CLINICAL INVESTIGATION AND VALIDATION OF N6-METHYLADENOSINE (m6A) READER IGF2BP2 IN PROMOTING THE PROGRESSION OF INTRAHEPATIC CHOLANGIOCARCINOMA (AASLD 2022)
Collectively, our study suggested that m6A-related regulators play a significant role in the tumorigenesis of ICC, and demonstrate the oncogenic role of IGF2BP2, indicating that IGF2BP2 may act as a potential biomarker panel and therapeutic target for ICC patients.
Clinical
|
SOX2 • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
|
IGF2 overexpression
over1year
Altered expression of the IGF2‑H19 locus and mitochondrial respiratory complexes in adrenocortical carcinoma. (PubMed, Int J Oncol)
On the whole, the findings of the present study reveal the dysregulation of the IGF2‑H19 locus and mitochondrial respiration in ACC. These findings may provide a basis for the further understanding of the pathogenesis of ACC and may have potential values for diagnostics and treatment.
Journal
|
IGF2 (Insulin-like growth factor 2) • H19 (H19 Imprinted Maternally Expressed Transcript)
|
IGF2 overexpression
over1year
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. (PubMed, Nat Med)
Overexpression of IGF2 and L1CAM was associated with decreased response to neoadjuvant therapy. RNA-sequencing estimates of immune infiltration identified a subset of microsatellite-stable immune hot tumors with increased response and prolonged disease-free survival.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • APC (APC Regulator Of WNT Signaling Pathway) • IGF2 (Insulin-like growth factor 2) • L1CAM (L1 cell adhesion molecule)
|
KRAS mutation • APC mutation • IGF2 overexpression
over1year
Hepatocyte Deletion of IGF2 Prevents DNA Damage and Tumor Formation in Hepatocellular Carcinoma. (PubMed, Adv Sci (Weinh))
Looking at public TCGA data, HCC patients having high SRSF3 mRNA expression show poor survival, as do patients with alterations in known SRSF3-dependent splicing events. The results indicate that IGF2 overexpression in conjunction with reduced SRSF3 splicing activity could be a major cause of DNA damage and driver of liver cancer.
Journal
|
IGF2 (Insulin-like growth factor 2) • SRSF3 (Serine And Arginine Rich Splicing Factor 3)
|
IGF2 overexpression
almost2years
IGF2BP3‑stabilized SIX4 promotes the proliferation, migration, invasion and tube formation of ovarian cancer cells. (PubMed, Mol Med Rep)
Overexpression of IGF2BP3 also reversed the inhibitory effect of SIX4 interference on the malignant phenotypes of OC cells. Taken together, the results of the present study demonstrated that IGF2BP3‑stabilized SIX4 promoted the proliferation, metastasis and angiogenesis of SKOV3 cells.
Journal
|
IGF2 (Insulin-like growth factor 2) • SIX4 (SIX Homeobox 4)
|
IGF2 overexpression
|
dactinomycin
almost2years
Exosomal miR-543 Inhibits the Proliferation of Ovarian Cancer by Targeting IGF2. (PubMed, J Immunol Res)
Notably, upregulation of miR-543 led to increased cell supernatant glucose levels and suppressed cell growth, which was rescued by overexpression of IGF2. Exosomal miR-543 participates in the proteoglycan pathway to suppress cell proliferation by targeting IGF2 in OvCa.
Journal
|
IGF2 (Insulin-like growth factor 2) • MIR543 (MicroRNA 543)
|
IGF2 overexpression • miR-543 expression • miR-543 overexpression
almost2years
Long Non-coding RNA HOXA11-AS Facilitates Proliferation of Lung Adenocarcinoma Cells via Targeting the Let-7c-5p/IGF2BP1 Axis. (PubMed, Front Genet)
Experiments on mice confirmed that HOXA11-AS facilitated LUAD cell growth in vivo through regulating the let-7c-5p/IGF2BP1 axis. HOXA11-AS promoted LUAD cell proliferation by targeting let-7c-5p/IGF2BP1, which could be potential molecular targets for LUAD.
Journal
|
IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • HOXA11 (Homeobox A11) • Let-7c (MicroRNA Let-7c)
|
IGF2 overexpression • IGF2BP1 overexpression • HOXA11 overexpression
2years
RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner. (PubMed, J Exp Clin Cancer Res)
Collectively, our study uncovers the oncogenic role and potential mechanism of IGF2BP2, which serves as a m6A reader, in controlling lymphatic metastasis and EMT in HNSCC, suggesting that IGF2BP2 may act as a therapeutic target and prognostic biomarker for HNSCC patients with metastasis.
Journal
|
SNAI2 (Snail Family Transcriptional Repressor 2) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
|
IGF2 overexpression
2years
Adrenocortical Tumors in Children With Constitutive Chromosome 11p15 Paternal Uniparental Disomy: Implications for Diagnosis and Treatment. (PubMed, Front Endocrinol (Lausanne))
Tumor weight ranged from 21.5 g to 550 g. Despite poor prognostic features at presentation, such as pulmonary metastasis, bilateral adrenal involvement, and large tumors, all patients are alive 8-21 years after cancer diagnosis. Our observations suggest that children with ACT and wild type TP53, irrespective of their age, should be screened for germline abnormalities in chromosome 11p15.
Clinical • Journal
|
TP53 (Tumor protein P53) • IGF2 (Insulin-like growth factor 2)
|
TP53 wild-type • IGF2 overexpression
2years
IGF2BP2 Induces U251 Glioblastoma Cell Chemoresistance by Inhibiting FOXO1-Mediated PID1 Expression Through Stabilizing lncRNA DANCR. (PubMed, Front Cell Dev Biol)
This study aims to investigate the mechanism underlying IGF2 mRNA-binding protein 2 (IGF2BP2) and long noncoding RNA DANCR in etoposide resistance of glioblastoma (GBM) cells...FOXO1 promoted the transcriptional expression of PID1, enhancing the chemotherapy sensitivity of GBM cells, but overexpression of PID1 reversed the impact of IGF2BP2. Collectively, IGF2BP2 inhibits PID1 expression through the DANCR/FOXO1 axis, inducing drug resistance in GBM cells, and promoting glioma progression.
Journal
|
IGF2 (Insulin-like growth factor 2) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2)
|
IGF2 overexpression
|
etoposide IV
over2years
Insight into the role of IGF2BP1 in drug resistant mechanism of oral squamous cell carcinoma (PubMed, Shanghai Kou Qiang Yi Xue)
IGF2BP1 is significantly associated with cisplatin resistance in oral squamous cell carcinoma. IGF2BP1 can promote cisplatin resistance of oral squamous cells by activating downstream Akt signaling pathway.
Journal
|
IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1)
|
IGF2 overexpression • IGF2BP1 overexpression
|
cisplatin